The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Tirzepatide (TZP) is a new anti-obesity drug, and little is currently known about its effect on body composition (BC) in people with overweight or obesity. The aim of this study is to conduct a systematic review on the impact of TZP on BC compartments in this population during weight loss programs. Literature searches, study selection, method development, and quality appraisal were performed. The data were synthesized using a narrative approach, in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Of the 1379 papers retrieved, 6 randomized controlled trials met the inclusion criteria and were reviewed, revealing the following findings. Firstly, TZP was shown to result in a significant reduction in total fat mass (FM), visceral adipose tissue (VAT) and waist circumference (WC) between baseline and short as well as intermediate follow-ups. Compared to other anti-obesity medications (e.g., dulaglutide and semaglutide) taken over the same duration, TZP showed a superior decrease in body fat compartments (i.e., total FM, VAT and WC). Finally, the effect of TZP on fat-free mass (FFM) is still uncertain because the findings remain inconclusive. In conclusion, TZP appears to be an effective strategy for achieving significant improvements in body fat and its distribution, but additional investigations are still needed to determine the impact of TZP on lean mass in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Tirzepatide and exercise training in obesity
Bagherzadeh-Rahmani, B., Marzetti, E., Karami, E., Campbell, B. I., Fakourian, A., Haghighi, A. H., Mousavi, S. H., Heinrich, K. M., Brazzi, L., Jung, F., et al. (2024) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-242134 · Cited by 21 · cited 1×
“…were on medications other than TZP that might interfere with body weight and BC [20,21,34–45]; (ii) two due to the short duration of the TZP treatment [46,47]; (iii) one because it had an open-label lead-in period [48]; and (iv) five for not reporting data related to WC [49–53] (Figure 1).”
BackgroundRetractedTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 8×
“In detail, the findings on FFM derived from small-sampled trials, specifically three [54,55,58].”
BackgroundMethodResultInfluentialThe well-built clinical question: A key to evidence-based decisions
(1995) · ACP Journal Club · doi:10.7326/acpjc-1995-123-3-a12 · Cited by 2,931 · cited 2×
“We conducted a systematic review on the topic in adherence with the PICO framework [29] as follows: Population (P): Participants with overweight or obesity, however defined (i.e., body mass index (BMI), waist circumference (WC), fat mass (FM), visceral adipose tissue (VAT), etc.), estimated…”
BackgroundMethodInfluentialTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Hariton, E., & Locascio, J. J. (2018) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15199 · Cited by 1,604
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871 · cited 1×
“…were on medications other than TZP that might interfere with body weight and BC [20,21,34–45]; (ii) two due to the short duration of the TZP treatment [46,47]; (iii) one because it had an open-label lead-in period [48]; and (iv) five for not reporting data related to WC [49–53] (Figure 1).”
BackgroundAronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · cited 1×
“…were on medications other than TZP that might interfere with body weight and BC [20,21,34–45]; (ii) two due to the short duration of the TZP treatment [46,47]; (iii) one because it had an open-label lead-in period [48]; and (iv) five for not reporting data related to WC [49–53] (Figure 1).”
BackgroundFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 2×
“…removed on the following bases: (i) 14 because the participants were on medications other than TZP that might interfere with body weight and BC [20,21,34–45]; (ii) two due to the short duration of the TZP treatment [46,47]; (iii) one because it had an open-label lead-in period [48]; and (iv)…”
BackgroundDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Lifestyle modification approaches for the treatment of obesity in adults.
Wadden, T. A., Tronieri, J. S., & Butryn, M. L. (2020) · American Psychologist · doi:10.1037/amp0000517 · Cited by 661
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597 · cited 2×
“…TZP was revealed to have beneficial effects in terms of obesity comorbidities beyond WL [19], such as improvements in type 2 diabetes (T2D) [20], as well as cardiovascular diseases (CVDs) [21], non-alcoholic fatty liver disease (NAFLD) [22] and obstructive sleep apnea syndrome (OSAS) [23].”
BackgroundGastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
A new framework for the diagnosis, staging and management of obesity in adults
Busetto, L., Dicker, D., Frühbeck, G., Halford, J. C. G., Sbraccia, P., Yumuk, V., & Goossens, G. H. (2024) · Nature Medicine · doi:10.1038/s41591-024-03095-3 · Cited by 501
European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care
Durrer Schutz, D., Busetto, L., Dicker, D., Farpour-Lambert, N., Pryke, R., Toplak, H., Widmer, D., Yumuk, V., & Schutz, Y. (2019) · Obesity Facts · doi:10.1159/000496183 · Cited by 492
Preserving Healthy Muscle during Weight Loss
Cava, E., Yeat, N. C., & Mittendorfer, B. (2017) · Advances in Nutrition · doi:10.3945/an.116.014506 · Cited by 452 · cited 1×
“%) of FFM [70].”
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442 · cited 2×
“…as a basic method of assessing body composition, specifically representing a surrogate indirect expression of visceral adiposity (i.e., VAT) [59]—reported a significant reduction exceeding that determined by the placebo over the intermediate follow-up periods (i.e., 52 and 72 weeks) [56–58].”
BackgroundMethodKuriyan, R. (2018) · Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1777_18 · Cited by 384 · cited 1×
“Last but not least, the tools used in the majority of the included studies in this systematic review to assess the BC outcomes (DXA, ADP and MRI) have been widely validated within both clinical and research settings in this population [67].”
MethodMuscogiuri, G., El Ghoch, M., Colao, A., Hassapidou, M., Yumuk, V., Busetto, L., & Obesity Management Task Force (OMTF) of the European Association for the Study of Obesity (EASO) (2021) · Obesity Facts · doi:10.1159/000515381 · Cited by 289
Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00085-7 · Cited by 268
Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00188-7 · Cited by 226
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1710 · Cited by 208
Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., Milicevic, Z., Urva, S., Haupt, A., & Robins, D. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13979 · Cited by 208
Rosenstock, J., Frías, J. P., Rodbard, H. W., Tofé, S., Sears, E., Huh, R., Fernández Landó, L., & Patel, H. (2023) · JAMA · doi:10.1001/jama.2023.20294 · Cited by 156
Zhao, L., Cheng, Z., Lu, Y., Liu, M., Chen, H., Zhang, M., Wang, R., Yuan, Y., & Li, X. (2024) · JAMA · doi:10.1001/jama.2024.9217 · Cited by 132
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0277 · Cited by 131
Kadowaki, T., Chin, R., Ozeki, A., Imaoka, T., & Ogawa, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00187-5 · Cited by 131
Adverse Events Related to Tirzepatide
Mishra, R., Raj, R., Elshimy, G., Zapata, I., Kannan, L., Majety, P., Edem, D., & Correa, R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad016 · Cited by 110
Gao, L., Lee, B. W., Chawla, M., Kim, J., Huo, L., Du, L., Huang, Y., & Ji, L. (2023) · Nature Medicine · doi:10.1038/s41591-023-02344-1 · Cited by 104
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024) · Diabetologia · doi:10.1007/s00125-024-06144-1 · Cited by 102 · cited 1×
“This is in line with previous studies that have reported the superiority of TZP with respect to only GLP-1RA on other health outcomes, such as a recent systematic review that showed TZP had a more pronounced effect on HbA1c and weight reduction compared with semaglutide in people with TZP [65].”
ResultRisk of bias of randomized controlled trials published in orthopaedic journals
Chess, L. E., & Gagnier, J. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-76 · Cited by 83 · cited 1×
“Any disagreement was resolved by consensus discussion between both the reviewers and the principal investigator (PI) in order to take a final decision [33].”
BackgroundThe new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
Yabe, D., Kawamori, D., Seino, Y., Oura, T., & Takeuchi, M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14882 · Cited by 48 · cited 7×
“Yabe et al. [55] conducted the SURPASS J-mono study in Japan, which included 48 participants with T2D that were randomized to receive TZP at 5, 10 or 15 mg or du-laglutide at 0.75 mg once a week, over a follow-up period of 52 weeks.”
BackgroundMethodResultInfluentialMather, K. J., Mari, A., Heise, T., DeVries, J. H., Hua, M., Urva, S., Coskun, T., Haupt, A., Heine, R. J., Pratt, E., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae319 · Cited by 35 · cited 1×
“…on the following bases: (i) 14 because the participants were on medications other than TZP that might interfere with body weight and BC [20,21,34–45]; (ii) two due to the short duration of the TZP treatment [46,47]; (iii) one because it had an open-label lead-in period [48]; and (iv) five for…”
BackgroundBaker, D. E., Walley, K., & Levien, T. L. (2023) · Hospital Pharmacy · doi:10.1177/00185787221125724 · Cited by 21
Cited by
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“Tirzepatide has demonstrated total lean mass loss as well, although additional studies are needed to determine the impact of this [134,182].”
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101681 · Cited by 30
Schiavo, L., Santella, B., Mingo, M., Rossetti, G., Orio, M., Cobellis, L., Maurano, A., Iannelli, A., & Pilone, V. (2025) · Nutrients · doi:10.3390/nu17071216 · Cited by 22
“…review of randomized controlled trials investigating the effects of TZP on body composition in individuals with overweight and obesity has demonstrated that TZP significantly reduces total FM, visceral adipose tissue, and waist circumference over short-and intermediate-term follow-up periods [24].”
Aamir, A. B., Latif, R., Alqoofi, J. F., Almarzoq, F. A., Fallatah, J. O., Hassan, G. A., & Saab, F. A. A. A. A. (2025) · Journal of Clinical Medicine Research · doi:10.14740/jocmr6231 · Cited by 19
“While several systematic review (SR) and MA have compared the efficacy of tirzepatide or semaglutide in reducing body weight, the included trials mostly compared either of these drugs with placebo or any other medication [22-24, 28, 29].”
Metadata
- Authors
- Rochira, V., Greco, C., Boni, S., Costantino, F., Dalla Valentina, L., Zanni, E., Itani, L., & El Ghoch, M.
- Venue
- Diseases
- Publisher
- MDPI AG
- Published
- 2024-09-05
- Volume
- 12
- Issue
- 9
- Pages
- 204
- ISSN
- 2079-9721 (ISSN-L)
- OpenAlex
- W4402283038
- Cited by
- 34
- References
- 37
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.